학술논문
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
Document Type
article
Author
Benjamin E. Peterson; Deepak L. Bhatt; Ph. Gabriel Steg; Michael Miller; Eliot A. Brinton; Terry A. Jacobson; Steven B. Ketchum; Rebecca A. Juliano; Lixia Jiao; Ralph T. Doyle; Craig Granowitz; C. Michael Gibson; Duane Pinto; Robert P. Giugliano; Matthew J. Budoff; Jean‐Claude Tardif; Subodh Verma; Christie M. Ballantyne
Source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 6 (2022)
Subject
Language
English
ISSN
2047-9980
Abstract
Background Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical therapy. Methods and Results This post hoc analysis focused on the subset of patients with prior PCI enrolled in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), a multicenter, randomized, double‐blind, placebo‐controlled trial of icosapent ethyl versus placebo. Icosapent ethyl was added to statins in patients with low‐density lipoprotein cholesterol